Cognitive Impairment in Patients With Breast Cancer: Understanding the Impact of Chemotherapy and Endocrine Therapy

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2020 Mar 7

PMID 32142394

Citations 9

Authors

Patricia A Ganz

Kathleen Van Dyk

Affiliations

Soon will be listed here.

Citing Articles

Cognitive impairment following breast cancer treatments: an umbrella review.

Oliva G, Giustiniani A, Danesin L, Burgio F, Arcara G, Conte P Oncologist. 2024; 29(7):e848-e863.

PMID: 38723166 PMC: 11224991. DOI: 10.1093/oncolo/oyae090.

Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116).

Rapp S, Dressler E, Brown W, Wade 3rd J, Le-Lindqwister N, King D J Clin Oncol. 2024; 42(21):2546-2557.

PMID: 38709986 PMC: 11513887. DOI: 10.1200/JCO.23.01100.

Effectiveness of a Computerized Home-Based Cognitive Stimulation Program for Treating Cancer-Related Cognitive Impairment.

Tapia J, Taberner-Bonastre M, Collado-Martinez D, Pouptsis A, Nunez-Abad M, Dunabeitia J Int J Environ Res Public Health. 2023; 20(6).

PMID: 36981862 PMC: 10049401. DOI: 10.3390/ijerph20064953.

Use of Telemedicine to Improve Cognitive Functions and Psychological Well-Being in Patients with Breast Cancer: A Systematic Review of the Current Literature.

Giustiniani A, Danesin L, Pezzetta R, Masina F, Oliva G, Arcara G Cancers (Basel). 2023; 15(4).

PMID: 36831693 PMC: 9954456. DOI: 10.3390/cancers15041353.

COMT rs737865 mediates chemobrain in breast cancer patients with various levels of Ki-67.

Li W, Yu S, Duan X, Yao S, Tang L, Cheng H Am J Cancer Res. 2022; 12(7):3185-3197.

PMID: 35968333 PMC: 9360226.

References

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24(23):3726-34. DOI: 10.1200/JCO.2005.04.7985. View

Schagen S, van Dam F, Muller M, Boogerd W, Lindeboom J, Bruning P . Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999; 85(3):640-50. DOI: 10.1002/(sici)1097-0142(19990201)85:3<640::aid-cncr14>3.0.co;2-g. View

Dhillon H, Tannock I, Pond G, Renton C, Rourke S, Vardy J . Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy. J Cancer Surviv. 2017; 12(2):178-185. DOI: 10.1007/s11764-017-0656-6. View

Buwalda B, Schagen S . Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?. Life Sci. 2013; 93(17):581-8. DOI: 10.1016/j.lfs.2012.12.012. View

Wefel J, Kesler S, Noll K, Schagen S . Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2014; 65(2):123-38. PMC: 4355212. DOI: 10.3322/caac.21258. View

Ganz P, Petersen L, Castellon S, Bower J, Silverman D, Cole S . Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study. J Clin Oncol. 2014; 32(31):3559-67. PMC: 4209106. DOI: 10.1200/JCO.2014.56.1662. View

Vardy J, Dhillon H, Pond G, Rourke S, Bekele T, Renton C . Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. J Clin Oncol. 2015; 33(34):4085-92. PMC: 5683012. DOI: 10.1200/JCO.2015.63.0905. View

McEwen B, Milner T . Understanding the broad influence of sex hormones and sex differences in the brain. J Neurosci Res. 2016; 95(1-2):24-39. PMC: 5120618. DOI: 10.1002/jnr.23809. View

Boele F, Schilder C, de Roode M, Deijen J, Schagen S . Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer. Menopause. 2014; 22(1):17-25. DOI: 10.1097/GME.0000000000000271. View

10.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

11.

Van Dyk K, Crespi C, Petersen L, Ganz P . Identifying Cancer-Related Cognitive Impairment Using the FACT-Cog Perceived Cognitive Impairment. JNCI Cancer Spectr. 2020; 4(1):pkz099. PMC: 7015054. DOI: 10.1093/jncics/pkz099. View

12.

Castellon S, Ganz P, Bower J, Petersen L, Abraham L, Greendale G . Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2005; 26(7):955-69. DOI: 10.1080/13803390490510905. View

13.

Ahles T, Saykin A, McDonald B, Li Y, Furstenberg C, Hanscom B . Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010; 28(29):4434-40. PMC: 2988635. DOI: 10.1200/JCO.2009.27.0827. View

14.

Janelsins M, Heckler C, Peppone L, Ahles T, Mohile S, Mustian K . Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study. J Clin Oncol. 2018; :JCO2018786624. PMC: 6225503. DOI: 10.1200/JCO.2018.78.6624. View

15.

Sparano J, Gray R, Makower D, Pritchard K, Albain K, Hayes D . Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018; 379(2):111-121. PMC: 6172658. DOI: 10.1056/NEJMoa1804710. View

16.

Ganz P, Cecchini R, Julian T, Margolese R, Costantino J, Vallow L . Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2015; 387(10021):857-65. PMC: 4792658. DOI: 10.1016/S0140-6736(15)01169-1. View

17.

Wagner L, Gray R, Sparano J, Whelan T, Garcia S, Yanez B . Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. J Clin Oncol. 2020; 38(17):1875-1886. PMC: 7280048. DOI: 10.1200/JCO.19.01866. View

18.

van Dam F, Schagen S, Muller M, Boogerd W, vd Wall E, Droogleever Fortuyn M . Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998; 90(3):210-8. DOI: 10.1093/jnci/90.3.210. View

19.

Zwart W, Terra H, Linn S, Schagen S . Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?. Nat Rev Clin Oncol. 2015; 12(10):597-606. DOI: 10.1038/nrclinonc.2015.124. View

20.

Janelsins M, Heckler C, Peppone L, Kamen C, Mustian K, Mohile S . Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study. J Clin Oncol. 2016; 35(5):506-514. PMC: 5455314. DOI: 10.1200/JCO.2016.68.5826. View